Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. executive Sandra D. van der Vaart reported equity award activity and related tax withholding. On February 11, 2026, she exercised 376 Restricted Stock Units, converting them into 376 shares of common stock at an exercise price of $0 per share.
After this conversion, her directly held common stock position was 3,225.4864 shares before tax withholding. To cover tax obligations, 99 shares of common stock were withheld at a price of $289.89 per share, leaving 3,126.4864 shares of common stock held directly. Following the transaction, she also held 1,141 Restricted Stock Units, each representing the right to receive one common share as they vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. executive Mark S. Schroeder, EVP, President Diagnostics & COO, reported equity award activity involving restricted stock units and common shares. On February 11, 2026, he converted 806 Restricted Stock Units into an equal number of common shares at an exercise price of $0 per share.
To satisfy tax withholding obligations, 259 common shares were withheld at a price of $289.89 per share. Following these transactions, Schroeder directly holds 6,473.1426 shares of Labcorp common stock and 2,358 Restricted Stock Units, which each represent the right to receive one share of common stock.
Labcorp Holdings Inc. President and CEO Adam H. Schechter reported several equity transactions dated February 11, 2026. He sold 5,273 shares of common stock in an open-market transaction at $284.38 per share under a Rule 10b5-1 trading plan.
On the same day, he acquired 3,656 shares of common stock through the exercise and conversion of Restricted Stock Units, and 1,521 shares were withheld to cover tax obligations. Following these transactions, he directly held 89,478 common shares and 22,214 Restricted Stock Units, each RSU representing the right to receive one share of common stock.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa exercised restricted stock units and had shares withheld for taxes. On February 11, 2026, 230 restricted stock units converted into 230 shares of common stock. Of these, 68 shares were withheld to cover tax obligations at $289.89 per share.
Following these transactions, Oyegunwa directly held 4,106.253 shares of common stock and 2,190 restricted stock units. The vested units came from a grant scheduled to vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. executive Jonathan C. Meltzer, EVP, Operations, reported several equity transactions in Labcorp common stock. On February 11, 2026, he acquired 243 shares of common stock through the vesting and conversion of 243 Restricted Stock Units, each RSU representing one share of common stock.
To cover taxes related to this vesting, 70 shares were withheld at a price of $289.89 per share. On February 12, 2026, he executed an open‑market sale of 87 shares at an average price of $290.42 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions, he directly held 2,782.3256 shares of common stock and 2,694 Restricted Stock Units.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported equity award activity on February 11, 2026. She acquired 216 shares of common stock at $0 through the vesting and conversion of Restricted Stock Units, each representing one share of common stock. To cover tax withholding obligations, 62 shares of common stock were withheld at a price of $289.89 per share. After these transactions, she directly owned 3,442.4574 shares of common stock and 2,264 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Anita Z. Graham reported routine equity award activity. On February 11, 2026, 356 Restricted Stock Units converted into 356 shares of common stock at an exercise price of $0. To cover tax withholding, 109 shares of common stock were withheld at $289.89 per share. After these transactions, Graham directly owned 1,460 shares of common stock and 2,401 Restricted Stock Units, which continue to vest in three equal annual installments starting February 11, 2026.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, CMO & CSO, reported equity award activity in company stock. On February 11, 2026, he exercised 740 Restricted Stock Units, converting them into 740 shares of Common Stock at an exercise price of $0 per share.
To cover tax withholding obligations related to this vesting, 211 shares of Common Stock were withheld at a price of $289.89 per share, coded as a disposition for tax payment rather than an open-market sale. After these transactions, he directly held 31,606.9234 shares of Common Stock and 4,170 Restricted Stock Units, which vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. executive Megan D. Bailey reported equity compensation activity involving restricted stock units and common shares. On February 11, 2026, 403 restricted stock units were converted into 403 shares of common stock, increasing her directly held common shares to 4,286. To cover tax withholding obligations, 138 common shares were withheld at a price of $289.89 per share, leaving her with 4,148 directly owned common shares. Following these transactions, she also directly holds 2,827 restricted stock units that vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. director Paul Rothman reported acquiring shares through the vesting of equity awards. On February 11, 2026, he exercised 897 Restricted Stock Units, which converted into 897 shares of Labcorp common stock at an exercise price of $0 per share.
Following this transaction, Rothman directly owned 2,571 shares of Labcorp common stock and held 773 Restricted Stock Units, which represent rights to receive the same number of common shares. The filing reflects routine equity compensation vesting rather than an open‑market purchase or sale.